NZ741552A - Compositions and methods for treatment of homocystinuria - Google Patents

Compositions and methods for treatment of homocystinuria

Info

Publication number
NZ741552A
NZ741552A NZ741552A NZ74155216A NZ741552A NZ 741552 A NZ741552 A NZ 741552A NZ 741552 A NZ741552 A NZ 741552A NZ 74155216 A NZ74155216 A NZ 74155216A NZ 741552 A NZ741552 A NZ 741552A
Authority
NZ
New Zealand
Prior art keywords
eee
amino acid
eeee
mutant polypeptide
isolated
Prior art date
Application number
NZ741552A
Other languages
English (en)
Inventor
Jan Kraus
Tomas Majtan
Erez Bublil
Original Assignee
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/935,690 external-priority patent/US9675678B2/en
Application filed by Univ Colorado Regents filed Critical Univ Colorado Regents
Publication of NZ741552A publication Critical patent/NZ741552A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01022—Cystathionine beta-synthase (4.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NZ741552A 2015-11-09 2016-11-09 Compositions and methods for treatment of homocystinuria NZ741552A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/935,690 US9675678B2 (en) 2013-01-29 2015-11-09 Compositions and methods for treatment of homocystinuria
PCT/US2016/061050 WO2017083327A1 (en) 2015-11-09 2016-11-09 Compositions and methods for treatment of homocystinuria

Publications (1)

Publication Number Publication Date
NZ741552A true NZ741552A (en) 2022-04-29

Family

ID=58696136

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ741552A NZ741552A (en) 2015-11-09 2016-11-09 Compositions and methods for treatment of homocystinuria

Country Status (25)

Country Link
US (3) US11077175B2 (https=)
EP (3) EP3373922B1 (https=)
JP (2) JP7009364B2 (https=)
KR (1) KR102819396B1 (https=)
CN (2) CN115920016A (https=)
AU (2) AU2016354030B2 (https=)
BR (1) BR112018007768A2 (https=)
CY (1) CY1125113T1 (https=)
DK (2) DK3373922T3 (https=)
ES (2) ES2909914T3 (https=)
FI (1) FI3998067T3 (https=)
HR (2) HRP20220407T1 (https=)
HU (2) HUE058749T2 (https=)
IL (2) IL302198A (https=)
LT (2) LT3998067T (https=)
MX (1) MX2018005312A (https=)
NZ (1) NZ741552A (https=)
PL (2) PL3998067T3 (https=)
PT (2) PT3373922T (https=)
RS (2) RS63070B1 (https=)
SG (1) SG10201912972SA (https=)
SI (2) SI3373922T1 (https=)
SM (2) SMT202400463T1 (https=)
WO (1) WO2017083327A1 (https=)
ZA (1) ZA201802376B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
EP3373922B1 (en) 2015-11-09 2022-01-05 The Regents of The University of Colorado, A Body Corporate Compositions and methods for use in the treatment of homocystinuria
EP3612214A4 (en) * 2017-04-17 2021-01-20 The Regents of the University of Colorado, A Body Corporate ENZYME REPLACEMENT THERAPY OPTIMIZATION FOR THE TREATMENT OF HOMOCYSTINURIA
HRP20251579T1 (hr) * 2019-06-26 2026-01-30 Travere Therapeutics Switzerland Gmbh Pegilirana cistationin beta sintaza za enzimsku terapiju za liječenje homocistinurije
MX2022002571A (es) * 2019-09-03 2022-05-06 Travere Therapeutics Switzerland Gmbh Terapia enzimatica con cistationina beta-sintasa para el tratamiento de niveles elevados de homocisteina.

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS555429A (en) * 1978-06-23 1980-01-16 Nissan Motor Co Ltd Pressure regulator for fuel injection type gasoline engine
JPS5576559A (en) 1978-12-01 1980-06-09 Chiyou Lsi Gijutsu Kenkyu Kumiai Electron beam fine adjusting device
US5656425A (en) 1993-08-17 1997-08-12 Regents Of The University Of Colorado Screening for mutations by expressing cDNA segments
US5523225A (en) 1993-09-13 1996-06-04 Regents Of The University Of Colorado DNA sequence encoding human cystathionine β-synthase
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5635375A (en) 1995-01-09 1997-06-03 Regents Of The University Of Colorado Method of increasing the yield and heme saturation of cystathione β-synthase
CA2217696A1 (en) 1995-04-25 1996-10-31 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
WO1999055377A2 (en) 1998-04-28 1999-11-04 Applied Research Systems Ars Holding N.V. Polyol-ifn-beta conjugates
US6174696B1 (en) 1999-11-12 2001-01-16 Genzyme Corporation Method for the determination of homocysteine
GB2368641B (en) 1999-07-06 2004-10-06 Gen Atomics Methods and compositions for assaying analytes
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US20030091543A1 (en) 2001-10-26 2003-05-15 Klein Matthew B. Therapeutic cell preparation grafts and methods of use thereof
AU2003251550A1 (en) 2002-06-17 2003-12-31 The Regents Of The University Of Colorado HUMAN CYSTATHIONINE Beta-SYNTHASE VARIANTS AND METHODS OF PRODU CTION THEREOF
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
EP1396537A1 (en) * 2002-09-04 2004-03-10 Avidis SA Treatment of elevated plasma homocysteine
KR20060065663A (ko) 2003-07-31 2006-06-14 안티캔서, 인코포레이티드 생체 내에서의 유효성 향상을 위한, ＰＥＧ-ｒＭＥＴ아제와조합된 ＰＬＰ의 용도
CN1552905A (zh) 2003-12-18 2004-12-08 中国农业科学院茶叶研究所 一类茶树胱硫醚-γ-合成酶特异表达序列标签及其生物芯片
US8500720B2 (en) 2005-05-09 2013-08-06 Medtronic, Inc Method and apparatus for treatment of cardiac disorders
US20070010492A1 (en) 2005-07-11 2007-01-11 Generale Robert J Composition and method for reducing homocysteine caused by drugs containing methyl compounds
EP1878739A1 (en) 2006-07-14 2008-01-16 LEK Pharmaceuticals D.D. One step IMAC (MCAC) purification of proteins
JP6041454B2 (ja) * 2007-03-15 2016-12-07 株式会社 Ｄｎａセキュリティー研究所 Ｄｎａ含有インク組成物
JP5074146B2 (ja) 2007-03-30 2012-11-14 オリンパス株式会社 カプセル型医療装置
CN101322840A (zh) 2008-05-28 2008-12-17 中国人民解放军军事医学科学院卫生学环境医学研究所 一种人胱硫醚β-合成酶重组蛋白及应用
WO2011025964A2 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
EP2531597B1 (en) 2010-02-04 2021-01-06 AEMase, Inc. Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations therof
CA2803668A1 (en) 2010-07-01 2012-01-05 Isis Innovation Limited Treatment of cognitive disorders
US9034318B2 (en) 2011-08-30 2015-05-19 The Regents Of The University Of Colorado, A Body Corporate Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
US9243239B2 (en) 2012-03-26 2016-01-26 The Regents Of The University Of Colorado, A Body Corporate Purification of cystathionine beta-synthase
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
WO2015033279A1 (en) * 2013-09-04 2015-03-12 Mahesh Kandula Compositions and methods for the treatment of homocystinuria
JP6987741B2 (ja) 2015-07-24 2022-01-05 ハンミ ファーマシューティカル カンパニー リミテッド 生理活性ポリペプチド結合体の製造方法
EP3373922B1 (en) 2015-11-09 2022-01-05 The Regents of The University of Colorado, A Body Corporate Compositions and methods for use in the treatment of homocystinuria
EP3612214A4 (en) 2017-04-17 2021-01-20 The Regents of the University of Colorado, A Body Corporate ENZYME REPLACEMENT THERAPY OPTIMIZATION FOR THE TREATMENT OF HOMOCYSTINURIA
JP7002314B2 (ja) * 2017-12-13 2022-02-10 株式会社ブリヂストン 空気入りタイヤ
HRP20251579T1 (hr) 2019-06-26 2026-01-30 Travere Therapeutics Switzerland Gmbh Pegilirana cistationin beta sintaza za enzimsku terapiju za liječenje homocistinurije
MX2022002571A (es) 2019-09-03 2022-05-06 Travere Therapeutics Switzerland Gmbh Terapia enzimatica con cistationina beta-sintasa para el tratamiento de niveles elevados de homocisteina.

Also Published As

Publication number Publication date
RS63070B1 (sr) 2022-04-29
ZA201802376B (en) 2020-11-25
HUE058749T2 (hu) 2022-09-28
HRP20241491T1 (hr) 2025-01-03
ES2909914T3 (es) 2022-05-10
SMT202200151T1 (it) 2022-05-12
PT3998067T (pt) 2024-11-04
US20240091325A1 (en) 2024-03-21
US11077175B2 (en) 2021-08-03
US20200276282A1 (en) 2020-09-03
JP7009364B2 (ja) 2022-02-10
DK3373922T3 (da) 2022-03-28
CA3001625A1 (en) 2017-05-18
EP4487914A2 (en) 2025-01-08
SI3373922T1 (sl) 2022-05-31
US20220125896A1 (en) 2022-04-28
JP7482914B2 (ja) 2024-05-14
AU2016354030B2 (en) 2022-09-15
HUE068830T2 (hu) 2025-01-28
EP3998067A1 (en) 2022-05-18
US12194082B2 (en) 2025-01-14
SMT202400463T1 (it) 2025-01-14
IL258487B2 (en) 2023-09-01
PL3373922T3 (pl) 2022-05-02
KR20180074703A (ko) 2018-07-03
PL3998067T3 (pl) 2025-01-07
CN115920016A (zh) 2023-04-07
EP3373922B1 (en) 2022-01-05
US11771745B2 (en) 2023-10-03
IL302198A (en) 2023-06-01
PT3373922T (pt) 2022-03-28
KR102819396B1 (ko) 2025-06-12
IL258487B1 (en) 2023-05-01
JP2022050589A (ja) 2022-03-30
LT3998067T (lt) 2024-11-25
SI3998067T1 (sl) 2025-03-31
MX2018005312A (es) 2018-08-15
IL258487A (en) 2018-05-31
EP3373922A4 (en) 2019-05-15
EP3998067B1 (en) 2024-09-11
HK1258502A1 (en) 2019-11-15
LT3373922T (lt) 2022-04-11
AU2022287540B2 (en) 2025-02-27
CY1125113T1 (el) 2024-02-16
EP3373922A1 (en) 2018-09-19
WO2017083327A1 (en) 2017-05-18
CN108472277A (zh) 2018-08-31
EP4487914A3 (en) 2025-03-26
AU2022287540A1 (en) 2023-02-02
RS66106B1 (sr) 2024-11-29
HRP20220407T1 (hr) 2022-05-27
BR112018007768A2 (pt) 2018-10-23
AU2016354030A1 (en) 2018-05-10
ES2994256T3 (en) 2025-01-21
JP2018532763A (ja) 2018-11-08
SG10201912972SA (en) 2020-03-30
DK3998067T3 (da) 2024-10-28
FI3998067T3 (fi) 2024-10-31

Similar Documents

Publication Publication Date Title
NZ741552A (en) Compositions and methods for treatment of homocystinuria
Yoshikawa et al. Posterior sub-Tenon injections of repository corticosteroids in uveitis patients with cystoid macular edema.
Anderson The caveolae membrane system
Schwarzmann et al. Knock-down of the type 3 ryanodine receptor impairs sustained Ca2+ signaling via the T cell receptor/CD3 complex
Palm et al. Evolution of catalytic and regulatory sites in phosphorylases
Liebhaber et al. Translation inhibition by an mRNA coding region secondary structure is determined by its proximity to the AUG initiation codon
JP2017221711A5 (https=)
HUE025013T2 (hu) Szulfonamid-származékok
SA515360579B1 (ar) طريقة وجهاز لتشغيل خادم بروكسي
SA516371120B1 (ar) تصحيح قطع منشاري آلي لوضع نموذج رقمي جوفي ثلاثي الأبعاد من صور جهاز التصوير المقطعي المحوسب (cts)
UA128450C2 (uk) Склад на основі моноклонального атитіла до rsv
WO2003075129A3 (en) Methods, systems, and software for identifying functional bio-molecules
Al-Salem Splenectomy for children with thalassemia: total or partial splenectomy, open or laparoscopic splenectomy
MX2024005883A (es) Compuesto para el secuestro de anticuerpos no deseables en un paciente.
SG11202110150YA (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
Witzig Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.
Lipphaus et al. Three‐dimensional finite element analysis of the dural folds and the human skull under head acceleration
HUP0104476A2 (hu) Hidroxi-propil-mutil-cellulóz kapszulákban formázott gyógyszerkészítmények
Chandra et al. Test‐dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non‐malignant disorders
Pippi et al. Lingual displacement of an entire lower third molar. Report of a case with suggestions for prevention and management.
Lavy et al. Use of the novel atypical opioid tapentadol in goats (C apra hircus): pharmacokinetics after intravenous, and intramuscular administration
RU2014128612A (ru) Модифицированные пептиды и их применение для лечения аутоиммунных заболеваний
White et al. Analysis of the structural requirements for lysosomal membrane targeting using transferrin receptor chimeras
Kawahara et al. Rhinocerebral mucormycosis with temporal artery thrombosis in an adolescent following HLA-haploidentical stem cell transplantation
Soresi et al. Effects of cyclosporin A on various indices of cholestasis in kidney transplant recipients

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2023 BY COMPUTER PACKAGES INC

Effective date: 20221017

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2024 BY COMPUTER PACKAGES INC

Effective date: 20231017

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2025 BY COMPUTER PACKAGES INC

Effective date: 20241030

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2026 BY COMPUTER PACKAGES INC

Effective date: 20251017